ADICET BIO INC (ACET)

US0070021086 - Common Stock

2.47  +0.03 (+1.23%)

After market: 2.5 +0.03 (+1.21%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

ADICET BIO INC

NASDAQ:ACET (2/23/2024, 7:27:38 PM)

After market: 2.5 +0.03 (+1.21%)

2.47

+0.03 (+1.23%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap173.30M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ACET Daily chart

Company Profile

Adicet Bio, Inc. is a clinical stage biotechnology company, which engages in discovering and developing allogeneic gamma delta T cell therapies for cancer. The company is headquartered in Boston, Massachusetts and currently employs 132 full-time employees. The company went IPO on 2018-01-26. The firm is engaged in discovering and developing allogeneic gamma delta T cell therapies for cancer. The firm is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs) and chimeric adaptors (CAds), to enhance selective tumor targeting and facilitate innate and adaptive anti-tumor immune response for durable activity in patients. Its product candidate, ADI-001, is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20 used for the treatment of relapsed or refractory B-cell non-Hodgkins lymphoma (NHL). Its pipeline also includes ADI-925, which is a novel engineered CAd gamma delta T cell product candidate targeting tumor stress ligands. Its pipeline also includes additional internal gamma delta T cell therapy programs in discovery and preclinical development for both hematological malignancies and solid tumors.

Company Info

ADICET BIO INC

200 Berkeley Street, 19th Floor

Boston MASSACHUSETTS 02116

P: 16174822333

CEO: Chen Schor

Employees: 132

Website: https://www.adicetbio.com/

ACET News

News Image10 days ago - Seeking AlphaJones upgrades Adicet to buy, cites upcoming catalysts (NASDAQ:ACET)

Jones Trading has upgraded its rating of Adicet Bio (ACET) to buy, citing “robust” interest in the cell therapy space. Jones said it sees approximately ten upco

News Image18 days ago - Adicet Bio, Inc.Adicet Bio to Participate in a Fireside Chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
News Image23 days ago - Adicet Bio, Inc.Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
News Image26 days ago - Market News VideoMonday 1/29 Insider Buying Report: ACET, CATX
News Imagea month ago - Adicet Bio, Inc.Adicet Bio, Inc. Announces Closing of $98 Million Public Follow-On Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
News Imagea month ago - Seeking AlphaAdicet Bio announces pricing of public offering (NASDAQ:ACET)

Adicet Bio announces the pricing of its public offering, with expected gross proceeds of $85.2M, to close on January 25, 2024.

ACET Twits

Here you can normally see the latest stock twits on ACET, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example